Die schöne PRANA

Kosmonova buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
  27.11.13      4,73      4,80§4,62 4,70 $ 136.774 0,64 M

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  29.11.13      4,74      4,96§4,725 4,91 $ 116.747 0,57 M

GrB

  15:42:20§5,1899 $
       100          §
  15:42:20§5,19 $
       100          §
  15:42:20§5,1899 $
       100          §
  15:42:20§5,19 $
       200          §
  15:42:20§5,1899 $
       100          §
  15:42:20§5,19 $
       100          §
  15:42:20§5,1899 $
       100          §
  15:42:20§5,1898 $
       800          §
  15:42:20§5,1899 $
       800          §
  15:42:20§5,19 $
       100          §
  15:42:20§5,1899 $
     1.950          §
  15:42:20§5,19 $
     1.850          §
  15:42:20§5,1899 $
       600          §
  15:41:35§5,1501 $
     1.000          §
  15:41:02§5,15 $
     1.000          §
  15:40:05§5,1799 $
       100          §
  15:40:05§5,19 $
     1.000          §
  15:40:05§5,18 $
       100          §
  15:40:04§5,179 $
     2.900          §
  15:39:01§5,1899 $
       120          §
  15:38:43§5,19 $
     1.000          §
  15:38:26§5,1401 $
       400          §
  15:38:08§5,19 $
       700          §
  15:37:52§5,2155 $
     2.700          §
  15:37:52§5,21 $
     1.500          §
  15:37:52§5,2065 $
     1.500          §
  15:37:52§5,21 $
       800          §
  15:37:52§5,2065 $
       800          §
  15:37:34§5,2099 $
     1.200          §
  15:37:23§5,1909 $
     1.000          §
  15:36:52§5,21 $
       300          §
  15:36:38§5,2299 $
       200          §
  15:36:17§5,1999 $
     1.000          §
  15:36:17§5,20 $
     3.000          §
  15:36:00§5,17 $
       129          §
  15:35:58§5,15 $
     3.000          §
  15:35:49§5,15 $
       500          §
  15:35:45§5,13 $
       800          §
  15:35:42§5,13 $
     1.000          §
  15:35:30§5,13 $
       100          §
  15:35:30§5,12 $
       142          §
  15:35:22§5,11 $
       100          §
  15:35:16§5,12 $
       100          §
  15:35:15§5,12 $
       329          §
  15:35:00§5,11 $
       100          §
  15:35:00§5,12 $
       329          §
  15:34:45§5,11 $
       100          §
  15:34:45§5,12 $
       400          §
  15:34:45§5,106 $
       100          §
  15:34:31§5,11 $
     1.000          §
  15:34:30§5,11 $
       329          §
  15:34:27§5,1099 $
     1.500          §
  15:34:19§5,1099 $
       750          §
  15:34:19§5,11 $
       150          §
  15:34:19§5,1099 $
       250          §
  15:34:19§5,11 $
       100          §
  15:33:30§5,10 $
       100          §
  15:32:56§5,0601 $
     1.000          §
  15:32:46§5,1199 $
     1.000          §
  15:32:45§5,12 $
     4.600          §
  15:32:44§5,12 $
     3.000          §
  15:32:44§5,09 $
       400          §
  15:32:42§5,07 $
       412          §
  15:32:16§5,06 $
       100          §
  15:31:26§5,0417 $
     1.500          §
  15:30:55§5,04 $
       200          §
  15:30:45§5,069 $
       100          §
  15:30:40§5,01 $
       200          §
  15:30:00§5,00 $
14.825

GrB

RTK 5,65  $ SKP +15,07 EK 4,91 $ last shares 100 full realtime 1.175.019 peak 5,73

buran und MfG und danke und weitermachen

Datum Erster Hoch Tief Schluss     Stücke Volumen
  02.12.13      5,00      5,73§5,00 5,72 $ 1.353.036 7,46 M

GrB

5.72 Up 0.81(16.50%) Dec 2, 4:00PM EST|After Hours : 5.60 Down 0.12 (2.10%) Dec 2, 7:07PM EST

Prev Close: 4.91
     Open:      5.00§
      Bid:§5.11 x 200
      Ask:§5.88 x 600
1y Target Est: 6.00
     Beta:§0.27
Next Earnings Date: N/A
Day's Range: 5.00 - 5.73
52wk Range: 2.03 - 6.50
   Volume:§1,360,362
Avg Vol (3m): 656,792
Market Cap: 222.89M
P/E (ttm): N/A
EPS (ttm): -0.24
Div & Yield: N/A (N/A)
finance.yahoo.com/q?s=PRAN&ql=1

is a world leader in addressing the role of biological metals in human disease.

Abundant scientific evidence suggests that many age-related conditions result from pathological interactions between selected metals and target proteins. The company has developed a proprietary library of chemical compounds that target these interactions, preventing protein aggregation and corruption.

The mission of the company is to develop disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's diseases. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration.
www.pranabio.com/

focused on the research and development of treatments for Alzheimer's Disease and other major neurodegenerative disorders. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

The Company was incorporated in 1997 in Melbourne, Australia and listed on the on the Australian Stock Exchange in 2000 (ASX: PBT) and NASDAQ in 2002 (Nasdaq: PRAN).
www.pranabio.com/default.asp?contentID=596

www.pranabio.com/default.asp?contentID=662 GrB

Financial Year 2013
Form 6K

Financial Year 2012
Appendix 4D
Form 6K

Financial Year 2011
Appendix 4D
Form 6K

Financial Year 2010
Appendix 4D
Form 6K

Financial Year 2009
Appendix 4D
Form 6K

Financial Year 2008
Appendix 4D
Form 6K

Financial Year 2007
Appendix 4D
Form 6K

Financial Year 2006
Appendix 4D
Form 6K

Financial Year 2005
Appendix 4D
Form 6K

Financial Year 2004
Appendix 4D
www.pranabio.com/default.asp?contentID=663

Financial Year 2014
Appendix 4C September 2013

Financial Year 2013
Appendix 4C June 2013
Appendix 4C March 2013
Appendix 4C December 2012
Appendix 4C September 2012

Financial Year 2012
Appendix 4C June 2012
Appendix 4C March 2012  
Appendix 4C December 2011
Appendix 4C September 2011

Financial Year 2011
Appendix 4C June 2011
Appendix 4C March 2011
Appendix 4C December 2010
Appendix 4C September 2010

Financial Year 2010
Appendix 4C June 2010
Appendix 4C March 2010
Appendix 4C December 2009
Appendix 4C September 2009

Financial Year 2009
Appendix 4C June 2009
Appendix 4C March 2009
Appendix 4C December 2008
Appendix 4C September 2008

Financial Year 2008
Appendix 4C June 2008
Appendic 4C March 2008
Appendix4C December 2007
Appendix 4C September 2007

Financial Year 2007
Appendix 4C June 2007
Appendix 4C March 2007
Appendix 4C December 2006
Appendix 4C September 2006

Financial Year 2006
Appendix 4C June 2006
Appendix 4C March 2006
Appendix 4C December 2005
Appendix 4C September 2005

Financial Year 2005
Appendix 4C June 2005
Appendix 4C March 2005
Appendix 4C December 2004
Appendix 4C September 2004

Financial Year 2004
Appendix 4C June 2004
Appendix 4C March 2004
Appendix 4C December 2003
Appendix 4C September 2003

Financial Year 2003
Appendix 4C June 2003
Appendix 4C March 2003
Appendix 4C December 2002

Financial Year 2002
Appendix 4C March 2002
Appendix 4C December 2001
Appendix 4C September 2001

Financial Year 2001
Appendix 4C June 2001
www.pranabio.com/default.asp?contentID=664

www.pranabio.com/default.asp?contentID=681 GrB

www.pranabio.com/default.asp?contentID=630 GrB

www.pranabio.com/default.asp?contentID=658 GrB

RESULTS OF ANNUAL GENERAL MEETING


Thursday, 28th November 2013

The Company wishes to advise that all resolutions contained in the Notice of Meeting were carried on a
show of hands.

In accordance with Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following
information is provided in relation to the resolutions considered by Members of the Company at the Annual
General Meeting held today.



* The Chairman voted undirected proxies in his control in favour of all resolutions.


On behalf of the Board


Richard Revelins
Company Secretary
Prana Biotechnology Limited
www.pranabio.com/downloads/...%202013%20Results%20of%20AGM.pdf

www.pranabio.com/default.asp?contentID=629 GrB

Prana Provides Update on IMAGINE Trial and Extension Trial for
Alzheimer’s Disease:

Melbourne – Monday 18th November, 2013: Prana Biotechnology (NASDAQ:PRAN;
ASX:PBT) has today provided an update on the IMAGINE Phase 2 trial for Alzheimer’s
Disease and is pleased to report that 29 patients of the 42 patients originally enrolled into the
trial have now completed treatment.

The IMAGINE trial is a 12-month double-blind Phase 2 clinical trial of PBT2 in Alzheimer’s
patients. Patients who have completed the full 12-month term of the IMAGINE trial are
eligible for participation in an open-label Extension study. All participants in the Extension
study will receive a 250mg once daily oral dose of PBT2 for an additional 12 months.

So far, 24 patients (of a possible 29) have continued on to the Extension trial, with a further
patient currently being screened.

The company can also report that the Data Safety Monitoring Board (DSMB) has met for the
fifth and final time and, consistent with all previous safety reviews, has made no
recommendations to review or alter the original IMAGINE trial protocol.

The results of the IMAGINE Phase 2 trial are expected in March 2014.


About Prana Biotechnology Limited
Prana Biotechnology was established to commercialise research into age-related
neurodegenerative disorders. The Company was incorporated in 1997 and listed on the
Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002.
Researchers at prominent international institutions including The University of Melbourne,
The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a
teaching hospital of Harvard Medical School, contributed to the discovery of Prana’s
technology.

For further information please visit the Company’s web site at www.pranabio.com.
www.pranabio.com/downloads/...0on%20AD%20Clinical%20Trials.pdf

For further information please visit the Company’s web site at www.pranabio.com. Page 2 of 2
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the
Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has
tried to identify such forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar
expressions, but these words are not the exclusive means of identifying such statements. Such
statements include, but are not limited to any statements relating to the Company's drug development
program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company's drug development program, including, but not limited to, PBT2, and any other statements
that are not historical facts. Such statements involve risks and uncertainties, including, but not limited
to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing,
regulatory approval, production and marketing of the Company’s drug components, including, but not
limited to, PBT2, the ability of the Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug
compounds, including, but not limited to, PBT2, that could slow or prevent products coming to market,
the uncertainty of patent protection for the Company's intellectual property or trade secrets, including,
but not limited to, the intellectual property relating to PBT2, and other risks detailed from time to time
in the filings the Company makes with Securities and Exchange Commission including its annual
reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s
current expectations, but actual results may differ materially due to various factions including those
risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely
on those forward-looking statements as a prediction of actual future results.



Contacts:

USA:
Vivian Chen
Grayling
T: +1 646-284-9472
Vivian.Chen@grayling.com



Australia: Investor Relations
Rebecca Wilson
T: +61 3 8866 1216
E: rwilson@buchanwe.com.au



Media Relations
Ben Oliver
T: +61 3 8866 1233
E: boliver@buchanwe.com.au
www.pranabio.com/downloads/...bal%20neuroscience%20project.pdf

RTK 5,66  $ RTP -0,35 EK 5,68 $ last shares 500 full reltime 99.675 peak 5,80

buran und MfG und sowieso und überhaupt und weitermachen und lass krachen

Datum Erster Hoch Tief Schluss     Stücke Volumen
  04.12.13      5,80      5,80§5,56 5,79 $ 324.005 1,84 M

..solange die schöne PRANA inne Depots reinpasst ..wird keene Arbeit anjefasst ..schrumm schrumm schrumm ..wer nch ordert der iss dumm ..diedelbumm ..bumm ..bumm

buran & PRANA,Die Börsen Sissi Tausendschönsten

       100          §
  15:51:42§5,68 $
       100          §
  15:51:37§5,681 $
     1.500          §
  15:50:46§5,69 $
       275          §
  15:49:12§5,69 $
       500          §
  15:49:12§5,73 $
       500          §
  15:47:02§5,71 $
       100          §
  15:47:02§5,71 $
       100          §
  15:46:37§5,7199 $
       100          §
  15:46:16§5,7062 $
       300          §
  15:45:59§5,70 $
       452          §
  15:45:58§5,7101 $
       100          §
  15:45:58§5,71 $
       100          §
  15:45:56§5,71 $
       100          §
  15:45:55§5,70 $
       298          §
  15:45:55§5,70 $
       250          §
  15:44:40§5,701 $
       300          §
  15:44:40§5,701 $
       290          §
  15:44:40§5,701 $
       300          §
  15:44:40§5,72 $
     2.000          §
  15:44:40§5,72 $
       500          §
  15:44:40§5,72 $
     1.000          §
  15:44:21§5,721 $
       100          §
  15:44:20§5,721 $
       900          §
  15:44:19§5,721 $
     1.000          §
  15:44:12§5,72 $
       100          §
  15:44:11§5,74 $
       100          §
  15:44:11§5,72 $
       800          §
  15:44:11§5,74 $
       100          §
  15:43:29§5,7402 $
       300          §
  15:43:03§5,741 $
       712          §
  15:43:02§5,76 $
       700          §
  15:43:02§5,78 $
       200          §
  15:43:02§5,77 $
       200          §
  15:41:40§5,7999 $
     1.000          §
  15:39:38§5,8199 $
       500          §
  15:38:58§5,81 $
       100          §
  15:38:54§5,82 $
     1.000          §
  15:38:40§5,82 $
       100          §
  15:38:37§5,82 $
       400          §
  15:37:38§5,76 $
       200          §
  15:37:37§5,7601 $
       200          §
  15:37:37§5,79 $
     1.600          §
  15:37:14§5,761 $
     2.500          §
  15:36:22§5,7799 $
       800          §
  15:36:20§5,78 $
       369          §
  15:35:50§5,77 $
       100          §
  15:35:47§5,7603 $
       500          §
  15:35:42§5,78 $
       500          §
  15:35:34§5,79 $
     1.800          §
  15:35:31§5,79 $
       200          §
  15:35:30§5,80 $
     1.825          §
  15:35:19§5,80 $
       100          §
  15:35:19§5,8001 $
       700          §
  15:35:19§5,80 $
       100          §
  15:35:19§5,8001 $
       300          §
  15:35:13§5,81 $
       100          §
  15:35:11§5,8101 $
       187          §
  15:35:10§5,82 $
       678          §
  15:34:51§5,82 $
     3.500          §
  15:34:51§5,85 $
     5.040          §
  15:34:51§5,86 $
     1.500          §
  15:34:32§5,86 $
     1.000          §
  15:34:18§5,8799 $
       200          §
  15:34:09§5,88 $
       100          §
  15:34:07§5,88 $
       100          §
  15:33:59§5,8701 $
       400          §
  15:33:59§5,88 $
       600          §
  15:33:51§5,85 $
     5.000          §
  15:33:28§5,85 $
       600          §
  15:33:28§5,86 $
       200          §
  15:33:28§5,85 $
       200          §
  15:33:25§5,89 $
       100          §
  15:33:25§5,88 $
       580          §
  15:33:22§5,85 $
     1.060          §
  15:33:19§5,85 $
       100          §
  15:33:18§5,85 $
       500          §
  15:33:16§5,85 $
       600          §
  15:33:12§5,8499 $
       100          §
  15:33:12§5,85 $
       100          §
  15:32:49§5,85 $
       600          §
  15:31:00§5,8201 $
     2.000          §
  15:30:40§5,8499 $
       500          §
  15:30:40§5,85 $
       500          §
  15:30:09§5,84 $
     1.000          §
  15:30:00§5,83 $
1.476

GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  05.12.13      5,83      5,89§5,45 5,70 $ 348.601 1,83 M

GrB

:::::::::::::: 5,71 $ +0,18% +0,01 $
In Euro: 4,1667 € | Nasdaq, 06.12.13 ,GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.12.13      5,70      5,76§5,50 5,71 $ 193.623 1,09 M

..Aktien mögen sowas ..Haut so weiss wie Elfenbein ..das Haar so schwarz wie Ebenholz ..Lippen süsser als roter Wein ..nie hab ich schöneres gesehen ..sagt wer ist das holde Kind ..das kann nur meine schöne PRANA sein ..ei fei ..;o) ..nuff ..tüff .tüff

buran & PRANA,Das Börsen Liebesnest Molkereiweg 23